GeneReach Biotechnology
GeneReach Biotechnology Corp. is a Taiwan-based molecular diagnostics company that designs, manufactures, and distributes point-of-care nucleic acid detection systems using proprietary insulated isothermal PCR (iiPCR) technology, serving aquaculture, veterinary, human diagnostics, food safety, and agriculture markets across 40+ countries via 30+ distributors.
- Company typePublic
- Founded2004
- HeadquartersTaichung, Taiwan
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
GeneReach Biotechnology firmographics
Firmographics- Name
- GeneReach Biotechnology
- Legal name
- GeneReach Biotechnology Corp. (瑞基海洋生物科技股份有限公司)
- Website
- https://genereach.com
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GeneReach Biotechnology Corp. is a Taiwan-based molecular diagnostics company that designs, manufactures, and distributes point-of-care nucleic acid detection systems using proprietary insulated isothermal PCR (iiPCR) technology, serving aquaculture, veterinary, human diagnostics, food safety, and agriculture markets across 40+ countries via 30+ distributors.
- Ownership category
- akta.pro rank
GeneReach Biotechnology industry classification
Industry- Product category
- Molecular Diagnostics / In Vitro Diagnostics
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Rapid On-Site Environmental Testing Kits & Instruments (Lateral Flow, PCR, ATP Devices) (AFALAEAK), Pathogen & Disease Diagnostics Services (Plant, Soil, Water) (AFACAKAG)
Keywords
Where GeneReach Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Taichung
- HQ country
- Taiwan
- HQ region
- Asia
Offices3 records
Markets served
GeneReach Biotechnology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Instrument Sales: Sale of nucleic acid detection instruments including POCKIT™ Central, POCKIT™ Micro Series, taco™ mini, and related equipment. Instruments are sold with 1-year warranty and include various throughput options (1-8 samples per run)
- Reagents & Consumables: Recurring revenue from nucleic acid extraction reagents, iiPCR-specific reagents, IVD assays, and consumables. Includes taco™ DNA/RNA extraction kits (320 reactions/set), POCKIT reagents, and human IVD assays for diseases such as SARS-CoV-2 and Dengue
- Training Services: Training programs and support services for product usage and applications
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
GeneReach Biotechnology product offering
Product offeringCore offering
GeneReach develops, manufactures, and sells portable point-of-care nucleic acid detection instruments (POCKIT™ analyzers, taco™ extraction systems, cubee™ centrifuge) and proprietary iiPCR-based reagent kits and IVD assays. Its products enable rapid PCR-quality molecular diagnostics (~1 hour, 10-copy sensitivity) for aquaculture disease monitoring, veterinary point-of-care testing, human clinical diagnostics (e.g., SARS-CoV-2, Dengue), food safety, and agricultural pathogen screening, and are distributed globally through 30+ distributors.
Product overview
GeneReach Biotechnology offers a comprehensive point-of-care molecular diagnostics portfolio centered on its proprietary insulated isothermal PCR (iiPCR) technology. The core product line includes the POCKIT™ Central automated analyzer and POCKIT™ Micro Series handheld analyzers, which work in conjunction with the taco™ nucleic acid extraction systems (mini and standard models) and various reagent kits. The product ecosystem spans human IVD assays (including SARS-CoV-2 and Dengue), aquaculture disease detection (IQ2000™ and IQ REAL™ systems), and veterinary diagnostics. All products are manufactured under ISO 13485 and GMP quality management systems, with applications across human health, aquaculture, agriculture, food safety, and companion animal industries.
Differentiator
Problem solved
Functional benefit
Brands
- POCKIT: Point-of-care nucleic acid detection platform including POCKIT Central, POCKIT Micro Series, and POCKIT combo mobile laboratory
- taco
- cubee
- IQ2000
- IQ REAL
Products and services
- POCKIT™ Central Nucleic Acid Analyzer
Quantifiable outcome
- Detection sensitivity up to 10 copies per reaction, equivalent to real-time PCR
- +3 more outcomes
Companies that use GeneReach Biotechnology
Customer profileSegments5 records
Ideal customer profiles4 records
GeneReach Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GeneReach Biotechnology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Global Distributor NetworkcoreGeneReach has established partnerships with more than 30 distributors worldwide to provide local sales support, technical assistance, and product distribution across different regions including Asia, Americas, Europe, Middle East, and Australia. These distributor partnerships enable market access and customer support in local languages and geographies.
Scale indicators4 records
GeneReach Biotechnology competitors and assessment
Company assessmentDirect peers
- BioMérieux (BioFire): Operates the BioFire FilmArray multiplex PCR panels, a leading syndromic molecular diagnostics franchise. Comparable on PCR-based IVD for infectious disease and on the razor-and-blade reagent model used by GeneReach.
- IDEXXX Laboratories: Global leader in veterinary diagnostics with a strong molecular and point-of-care franchise (e.g., SNAP, RealPCR). Comparable to GeneReach's veterinary/animal-health segment where IDEXX is the dominant reference-lab and in-clinic provider.
- Cepheid (Danaher): Maker of the GeneXpert point-of-care PCR system, the dominant cartridge-based molecular diagnostics platform in clinical and decentralised settings. Directly comparable to GeneReach on instrument-plus-cartridge architecture and CLIA-waivable point-of-care positioning.
Regional players
- Seegene: Korea-based developer of multiplex real-time PCR assays (Allplex), with overlapping infectious-disease menu and syndromic testing ambitions. Comparable on PCR-based human IVD reagents, although Seegene is oriented toward high-throughput labs rather than point-of-care.
- SD Biosensor: Korea-headquartered diagnostics company spanning rapid antigen tests, molecular diagnostics and clinical chemistry. Comparable on the molecular infectious-disease menu and on a regional Asian distribution model similar to GeneReach's.
Broad incumbents
- Bio-Rad Laboratories: Long-established PCR and droplet digital PCR (ddPCR) franchise plus clinical diagnostics business. Comparable on the underlying PCR instrumentation and reagents that GeneReach's iiPCR competes with at the benchtop and high-sensitivity tier.
- Thermo Fisher Scientific: Owns Applied Biosystems PCR instruments, MagMAX extraction kits and the Mesa Biotech Accula portable PCR platform acquired during COVID-19. Comparable across almost every layer of GeneReach's stack: instruments, extraction, reagents, and emerging point-of-care molecular.
- Zoetis: Largest pure-play animal health company with diagnostics, vaccines and pharma. Comparable on the livestock and companion-animal customer base that GeneReach serves through POCKIT veterinary assays.
- Abbott Diagnostics: Markets the ID NOW and m-PIMA systems, isothermal/portable molecular platforms that compete directly with POCKIT in rapid point-of-care nucleic acid testing; broader portfolio and distribution reach give Abbott structural pricing advantages.
Emerging players
- Molbio Diagnostics: India-based maker of the Truenat point-of-care real-time PCR platform, focused on resource-limited settings and tuberculosis/HIV testing. Comparable on portable PCR hardware, low-infrastructure positioning, and emerging-market go-to-market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
GeneReach Biotechnology social profiles
Digital presenceGeneReach Biotechnology compliance and trust
Trust signalCompliance8 records
GeneReach Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneReach Biotechnology leadership team
Management profileNumber of profiles
Profiles7 records
GeneReach Biotechnology subsidiaries and ownership
Company hierarchySubsidiaries1 record
GeneReach Biotechnology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneReach Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneReach Biotechnology
What does GeneReach Biotechnology do?
GeneReach develops, manufactures, and sells portable point-of-care nucleic acid detection instruments (POCKIT™ analyzers, taco™ extraction systems, cubee™ centrifuge) and proprietary iiPCR-based reagent kits and IVD assays. Its products enable rapid PCR-quality molecular diagnostics (~1 hour, 10-copy sensitivity) for aquaculture disease monitoring, veterinary point-of-care testing, human clinical diagnostics (e.g., SARS-CoV-2, Dengue), food safety, and agricultural pathogen screening, and are distributed globally through 30+ distributors.
Is GeneReach Biotechnology a public or private company?
GeneReach Biotechnology is a public company. It is classified as public and is currently operating.
When was GeneReach Biotechnology founded?
GeneReach Biotechnology was founded in 2004. It employs 51 to 100 people.
Where is GeneReach Biotechnology based?
GeneReach Biotechnology is headquartered in Taichung, Taiwan, in the Asia region.
How does GeneReach Biotechnology make money?
Three revenue lines are on record. Instrument Sales are the primary driver. The others are reagents & Consumables and training Services.
Who are GeneReach Biotechnology's main competitors?
Direct peers on record are BioMérieux (BioFire), IDEXXX Laboratories and Cepheid (Danaher). Regional players are Seegene and SD Biosensor. Broad incumbents are Bio-Rad Laboratories, Thermo Fisher Scientific, Zoetis and Abbott Diagnostics. Molbio Diagnostics is listed as an emerging player.
Does GeneReach Biotechnology have an API?
No public API is recorded for GeneReach Biotechnology.
What industry is GeneReach Biotechnology in?
GeneReach Biotechnology's product category is Molecular Diagnostics / In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 334516 and its SIC code is 2835.